BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 12204713)

  • 1. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy.
    Diestelhorst M; Nordmann JP; Toris CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S155-61. PubMed ID: 12204713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study.
    Emmerich KH
    Graefes Arch Clin Exp Ophthalmol; 2000 Jan; 238(1):19-23. PubMed ID: 10664047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latanoprost and cholinergic agonists in combination.
    Toris CB; Alm A; Camras CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S141-7. PubMed ID: 12204711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
    Hoyng PF; Rulo A; Greve E; Watson P; Alm A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma.
    Ozdemir M; Ozdemir G
    Jpn J Ophthalmol; 2003; 47(1):72-6. PubMed ID: 12586182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
    Simmons ST; Samuelson TW
    Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.
    Feldman RM
    Expert Opin Pharmacother; 2004 Apr; 5(4):909-21. PubMed ID: 15102573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latanoprost versus combined timolol and dorzolamide.
    Bron AM; Emmerich KH
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S148-54. PubMed ID: 12204712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
    Zhang WY; Po AL; Dua HS; Azuara-Blanco A
    Br J Ophthalmol; 2001 Aug; 85(8):983-90. PubMed ID: 11466259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four years later: a clinical update on latanoprost.
    Ravinet E; Mermoud A; Brignoli R
    Eur J Ophthalmol; 2003 Mar; 13(2):162-75. PubMed ID: 12696636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.